

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Shigeya SUZUKI et al.

Serial No : 10/567,095 (National Stage of PCT/JP2004/011509)

Filed : February 3, 2006 (I.A. Filed: August 4, 2004)

For : METHOD OF JUDGING FATIGUE



INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98, Applicants hereby direct the Examiner's attention to the following documents cited in the International Search Report for International Application PCT/JP2004/011509 of which the above-referenced application is a National Phase:

- (1) Wong R., et al., "Skeletal Muscle Metabolism in the Chronic Fatigue Syndrome", CHEST, vol. 102, no. 6, 1992, pp.1716-1722; Applicants note that this document is also cited and discussed at page 4, line 18 of the present application;
- (2) McCully K., et al., "Blood flow and muscle metabolism in chronic fatigue syndrome", Clinical Science, vol. 104, June 2003, pages 641-647;

- (3) Forsyth L., et al, "Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome", ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY, vol. 82, no. 2, 1999, pages 185-191.

Applicants further direct the Examiner's attention to the following documents cited and discussed in the present application:

- (4) Kuratsune H., Igaku no Ayumi (Progress of Medical Science), February 1, 2003, vol. 204, no. 5, pp.381-386; Applicants note that this document is cited and discussed at page 2, line 3 of the present application;
- (5) Minowa M., "Actual state and Risk Factors of Fatigue in Local Society", welfare science research funds subsidy, health science overall research project "Research on the actual condition of fatigue, and studies on fatigue relieving means for health promotion", Research Achievement Report, 2000, pp. 19-44; Applicants note that this document is cited and discussed at page 2, line 13 of the present application;
- (6) Kitani T., "CFS no Gainen (Concept of CFS)", Rinsho Kagaku (Clinical Chemistry), 1993, vol. 29, no. 6, pp. 663-668; Applicants note that this document is cited and discussed at page 2, line 23 of the present application;
- (7) Kajimoto O., Igaku No Ayumi (Progress of Medical Science), February 1, 2003, vol. 204, no. 5, pp 377-380; Applicants note that this

document is cited and discussed at page 3, line 15 of the present application;

- (8) JP 5-3798 A, January 14, 1993, accompanied by an English language abstract thereof (provided by esp@cenet); Applicants note that this document is cited and discussed at page 4, line 5 of the present application;
- (9) Sahlin K., "Plasma hypoxanthine and ammonia in humans during prolonged exercise", European Journal of Applied Physiology, 1999, vol. 80, pp. 417-422; Applicants note that this document is cited and discussed at page 4, line 13 of the present application;

Copies of the above-listed documents and the International Search Report (in English) for International Application PCT/JP2004/011509 are enclosed together with a completed copy of the PTO-1449 Form listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

If there should be any questions, the Examiner is invited to contact the
undersigned at the telephone number listed below.

Respectfully submitted,
Shigeya SUZUKI et al.



Bruce H. Bernstein
Reg. No. 29,027

Stephen M. Roylance
Reg. No. 31,296

May 25, 2006
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

FORM PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. P29129	Application No. 10/567,095
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant Shigeya SUZUKI et al.	MAY 25 2006 O I P E PATENT & TRADEMARK OFFICE LAPS
				Filing Date February 3, 2006	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
		5 - 3 7 9 8	01/14/93	JAPAN				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Wong R., et al., "Skeltalo Muscle Metabolism in the Chronic Fatigue Syndrome", CHEST, vol. 102, no. 6, 1992, pp.1716-1722.
2	McCully K., et al., "Blood flow and muscle metabolism in chronic fatigue syndrome", Clinical Science, vol. 104, June 2003, pages 641-647.
3	Forsyth L., et al., "Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome", ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY, vol. 82, no. 2, 1999, pages 185-191.
4	Kuratsune H., Igaku no Ayumi (Progress of Medical Science), February 1, 2003, vol. 204, no. 5, pp.381-386.
5	Minowa M., "Actual state and Risk Factors of Fatigue in Local Society", welfare science research funds subsidy, health science overall research project "Research on the actual condition of fatigue, and studies on fatigue relieving means for health promotion", Research Achievement Report, 2000, pp. 19-44.
6	Kitani T., "CFS no Gainen (Concept of CFS)", Rinsho Kagaku (Clinical Chemistry), 1993, vol. 29, no. 6, pp. 663-668.
7	Kajimoto O., Igaku No Ayumi (Progress of Medical Science), February 1, 2003, vol. 204, no. 5, pp 377-380.
8	Sahlin K., "Plasma hypoxanthine and ammonia in humans during prolonged exercise", European Journal of Applied Physiology, 1999, vol. 80, pp. 417-422.
9	an English language abstract thereof (provided by esp@cenet) JP 5-3798.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.